Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Consolidation immunotherapy following chemoradiotherapy (CRT) for stage III NSCLC is standard of care since the PACIFIC trial1. However, real-world outcomes often fall short of clinical trial data. Our aim was to audit real-world survival outcomes and post progression therapy at a single Australian institution of stage III NSCLC patients who underwent CRT and consolidation Durvalumab.